HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

heparin-binding EGF-like growth factor (HB-EGF)

Subscribe to New Research on heparin-binding EGF-like growth factor

amino acid sequence given in first source; 86-208 amino acid residues; a novel member of the epidermal growth factor (EGF) family, synthesized by human macrophages & macrophage-like U-937 cells; mitogenic for smooth muscle cells but not for epithelial cells

Also Known As:

HB-EGF; HB-EGF precursor; HBEGF protein, human; SF HB-EGF; diphtheria toxin receptor; diphtheria toxin receptors; heparin-binding EGF-like growth factor, human; heparin-binding epidermal growth factor-like growth factor precursor; receptor, diphtheria toxin; short form HB-EGF

Networked: 489 relevant articles (16 outcomes, 70 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Besner, Gail E: 43 articles (07/2015 - 03/2002)
2.	Higashiyama, Shigeki: 25 articles (09/2014 - 01/2002)
3.	Mekada, Eisuke: 24 articles (05/2015 - 05/2003)
4.	Miyamoto, Shingo: 23 articles (08/2015 - 08/2004)
5.	Yotsumoto, Fusanori: 20 articles (08/2015 - 05/2006)
6.	Kuroki, Masahide: 14 articles (08/2015 - 11/2007)
7.	Chen, Chun-Liang: 11 articles (06/2014 - 04/2010)
8.	Yagi, Hiroshi: 10 articles (08/2014 - 08/2004)
9.	Radulescu, Andrei: 10 articles (01/2013 - 08/2007)
10.	Yu, Fu-Shin X: 10 articles (11/2011 - 03/2004)

Related Diseases

1.	Ischemia 11/01/2005 - "Heparin-binding, EGF-like growth factor protected the intestine from injury when administered before injury and was also effective when administered during ischemia or even after injury. " 06/01/2014 - "In the current study, we investigated whether the ability of HB-EGF to protect the intestines from ischemia/reperfusion (I/R) injury was related to its effects on Wnt/β-catenin signaling in intestinal stem cells (ISC). " 09/01/2010 - "In the current study, we investigated the ability of HB-EGF to protect the lungs from remote organ injury after intestinal ischemia/reperfusion (I/R). " 06/01/2008 - "The aim of the current study was to evaluate the effect of HB-EGF gene disruption on intestinal restitution, angiogenesis, and long-term survival after intestinal ischemia/reperfusion (I/R) injury. " 05/01/1997 - "Immunohistochemical studies revealed that HB-EGF was produced predominantly in distal tubules in kidneys injured either by ischemia/reperfusion or aminoglycoside administration. "
2.	Neoplasms (Cancer) 09/01/2013 - "Studies show that HB-EGF expression is essential in oncogenesis of cancer-derived cell lines. " 06/10/2012 - "In the present study, we developed novel immunoliposomes targeting HB-EGF for cancer therapy. " 02/01/2010 - "This study not only associates Tgf-α and Hb-egf expression with wild-type Egfr oncogenicity but also ascribes the proangiogenic activity of Egfr in this tumor model to a novel mesenchymal Hb-egf/Egfr signaling axis, whereby endothelial and pericyte-derived Hb-egf activates Egfr specifically in tumor-associated perivascular cells, leading to increased pericyte coverage of the tumor endothelium and enhanced angiogenesis." 05/01/2006 - "Studies in vitro and in vivo have indicated that HB-EGF expression is essential for tumor formation of cancer-derived cell lines. " 08/01/2004 - "In vivo studies also demonstrated that tumor cells expressing s-HB-EGF or wild-type HB-EGF significantly enhanced tumorigenic potential in athymic nude mice and exerted an angiogenic effect, increasing the density and size of tumor blood vessels. "
3.	Wounds and Injuries (Trauma) 11/01/2010 - "The wound closure was significantly impaired in HB(-/-) MCECs and was improved by adding HB-EGF. " 07/01/2015 - "The multifunctional role of HB-EGF in the healing process and its enhanced efficacy when delivered by the coacervate make it a promising therapy for diabetic wounds. " 06/01/2005 - "Studies of wound healing revealed that wound closure was markedly impaired in keratinocyte-specific HB-EGF-deficient mice. " 07/01/2015 - "In full-thickness excisional wounds on NONcNZO10 diabetic mice, HB-EGF coacervate enhanced the proliferation and migration of epidermal keratinocytes, leading to accelerated epithelialization. " 07/01/2015 - "Coacervate delivery of HB-EGF accelerates healing of type 2 diabetic wounds."
4.	Anoxia (Hypoxia) 07/01/1998 - "Finally, HB-EGF-treated cells had a significantly improved proliferative ability compared with nontreated cells during recovery from hypoxia (P < .05). " 05/01/2013 - "We show that HB-EGF regulates the expression of VEGFA or ANGPTL4 via transcriptional regulation of hypoxia-inducible factor-1α and NF-κB. " 04/15/2013 - "Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia." 10/01/2012 - "HB-EGF significantly protected AF-MSCs and BM-MSCs from anoxia-induced apoptosis. " 01/01/2012 - "In addition, HB-EGF protected pericyte-like cells from anoxia-induced apoptosis. "
5.	Hyperplasia 01/01/2005 - "These results indicate that expression of HB-EGF and generation of its soluble form, followed by activation of EGFR and ErbB2, are pivotal processes in tRA-induced epidermal hyperplasia." 01/01/2005 - "tRA-induced epidermal hyperplasia was reduced both in the keratinocyte-specific HB-EGF null mice (K5-HB(del/del)) and knock-in mice expressing the uncleavable mutant form of HB-EGF (HB(uc/uc)), as compared with wild-type HB-EGF knock-in mice (HB(lox/lox)). " 01/01/2005 - "HB-EGF is normally expressed in epidermis of normal adult mice at very low levels, but topical tRA treatment results in epidermal hyperplasia, concomitant with the strong induction of HB-EGF expression in the suprabasal layer. " 12/01/2001 - "Further, it was shown that an antibody to HB-EGF-like growth factor inhibited retinoid-stimulated epidermal hyperplasia in organ culture and reduced proliferation in cultured keratinocytes. " 12/01/1998 - "These results support the hypothesis that the effects of RA on epidermal hyperplasia are mediated at least in part by HB-EGF, and suggest that signal transduction mechanisms other than or in addition to nuclear RA receptors contribute to this effect."

Related Drugs and Biologics

1.	Epidermal Growth Factor (EGF)
2.	Heparin (Liquaemin)
3.	Messenger RNA (mRNA)
4.	CRM197 (non-toxic variant of diphtheria toxin)
5.	Galectin 1 (LGALS1)
6.	Retinaldehyde (Retinal)
7.	Protein-Tyrosine Kinases (Tyrosine Kinase)
8.	tyrphostin AG 1478
9.	Matrix Metalloproteinases
10.	Retinoids

Related Therapies and Procedures

1.	Salvage Therapy
2.	Intraventricular Injections
3.	Resuscitation
4.	Heterologous Transplantation (Xenotransplantation)
5.	Transplants (Transplant)